Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. - Wikidata - awgldk - TriplyDB

Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.

Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.

http://www.wikidata.org/entity/Q37092262

about

The residual nonadrenergic contractile response to nerve stimulation of the mouse prostate is mediated by acetylcholine but not ATP in a comparison with the mouse vas deferens.Impact of lower urinary tract symptoms/benign prostatic hyperplasia treatment with tamsulosin and solifenacin combination therapy on erectile function The role of combination medical therapy in benign prostatic hyperplasia.Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes.Occurrence of overactive bladder in patients with benign prostatic hyperplasia in the Czech Republic.Efficacy and safety of propiverine and terazosine combination for one year in male patients with luts and detrusor overactivity.

P2860

Q34257555-7E4DDE7D-8A3B-465E-82AD-2CBA519ADE9E Q34567905-7B2D05FF-36F5-47A8-88AE-341F439FA4F9 Q34877827-1682E9AD-CFA5-4D55-A640-6361D21E2D64 Q35089850-2C40C62E-3546-49B1-B58C-A078AD172FD2 Q39294461-EFB200C7-0617-4CE3-989E-A62F697ABA09 Q44125663-6CFC85A7-5A1E-4DD5-BD4A-527DE106C129 Q48164988-C848FA1C-A869-4C2A-BDD8-EAEA4BB48C7C

P2860

Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.

http://www.wikidata.org/entity/Q37092262

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Anticholinergic therapy for lo ...... benign prostatic hyperplasia.

@en

Anticholinergic therapy for lo ...... benign prostatic hyperplasia.

@nl

type

label

Anticholinergic therapy for lo ...... benign prostatic hyperplasia.

@en

Anticholinergic therapy for lo ...... benign prostatic hyperplasia.

@nl

prefLabel

Anticholinergic therapy for lo ...... benign prostatic hyperplasia.

@en

Anticholinergic therapy for lo ...... benign prostatic hyperplasia.

@nl

P1433

Q37092262-E375EC31-84F8-4171-B417-1EB917731F6F

P1476

Q37092262-7F247F33-7CAA-44D7-A77B-A91EFAA45142

P2093

Q37092262-1DA01A86-CAB6-4638-8B3C-0E347568238A

Q37092262-DC498983-ACB1-4396-87E6-294CC13B6061

P2860

Q37092262-03BAF39D-D367-497A-B513-9E5183CD31AB

Q37092262-079680C2-040D-473E-99F8-38C9C7FBF2D9

Q37092262-18A0F0AB-FB5F-4434-B8A6-15829CD22744

Q37092262-2574A795-C85C-437E-A790-23FC5D4DB980

Q37092262-340761BB-B2EF-43B3-BB9C-1F83E606DEF4

Q37092262-36019E69-1E9C-460C-8D0F-3D88B30AEBD6

Q37092262-37810AD2-7C3B-4C2C-B80D-F23D83DCAD28

Q37092262-38E8888B-C192-4E7F-A547-62CDC7BF13CC

Q37092262-3D2E76C4-C427-46FD-8DC2-06A603413F99

Q37092262-3FBF3FE9-DBE0-4582-8A50-86FD66921211

P304

Q37092262-7C1C6267-0EDF-4CA9-B823-9892B972BBB7

P31

Q37092262-B3069F05-A7CA-41A8-95D9-1A9B8141AD0D

P356

Q37092262-0D28574B-3D69-4A19-901A-45980903BA01

P407

Q37092262-F3003AA7-532D-44B0-8842-D895D63DA18B

P433

Q37092262-9A910AEE-4C55-49CC-8AF7-1BF79DC3D688

P478

Q37092262-E75A6786-2E0D-4033-8B17-6DFEAAA213C5

P577

Q37092262-872B69D2-07B0-48F1-9761-93FA74F27F5F

P698

Q37092262-B4DB671D-B7DA-4D91-A132-9769A5475FD5

P356

P1433

Pharmacotherapy

P1476

Anticholinergic therapy for lo ...... benign prostatic hyperplasia.

@en

P2093

Lawrence A Frazee

http://www.w3.org/2001/XMLSchema#string

Patrick J Gallegos

http://www.w3.org/2001/XMLSchema#string

P2860

A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.

AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations.

Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.

Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia.

Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies.

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

Drug therapy of urinary urge incontinence: a systematic review.

Urinary incontinence in the community--analysis of a MORI poll.

Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents?

P304

356-365

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1592/PHCO.28.3.356

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2008-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18294115

http://www.w3.org/2001/XMLSchema#string